Breaking News Bar

Business News and Information

Audentes Therapeutics Inc (NQ: BOLD )

59.97 USD UNCHANGED

Last Price Updated: 5:31 PM EST, Jan 14, 2020 Add to My Watchlist

Price and Volume

Volume	0
Open	59.97
Bid (Size)	59.94 (380)
Ask (Size)	59.99 (1,683)
Prev. Close	59.97
Today's Range	59.97 - 59.97
52wk Range	N/A - N/A
Shares Outstanding	36,743,621
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – BOLD, INST, THOR

December 21, 2019

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – BOLD, AKS, INST, THOR

December 16, 2019

Performance

More News

AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm

December 16, 2019

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – INST, AKS, BOLD, SORL

December 10, 2019

UPDATE 1-Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 mln

December 26, 2019

Astellas Pharma buys Xyphos Biosciences, deal worth up to $665 mln

December 26, 2019

UPDATE 2-Roche dives deeper into gene therapy with $1.15 bln Sarepta licensing deal

December 23, 2019

TECD, TIF, BOLD, and WLH SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

December 16, 2019

Sarepta’s surprise FDA approval for rare disease drug excites investors

December 13, 2019

BOLD, MDCO, AYR, and PEGI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

December 10, 2019

Drugmakers have spent a record $342 billion on M&A in 2019

December 09, 2019

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

bottom clear

About Us